While NEK2 inhibitors have been widely established, and the efficacy was tested in both in vitro and in vivo in several types of cancer, including multiple myeloma, leukemia, gastric, colorectal, glioma, breast, and liver cancers, their effect on lung cancer requires further investigation [82]. Here, NEK2 is linked to plasma cell myeloma.